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Abstract: 
Introduction: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is presumably rare in Africa. Knowledge about the 
disease in Nigeria is limited as demonstrated by scanty articles on the subject. 
Objectives: To determine the pattern of  clinical presentation and outcome of  ADPKD among ADPKD patients. 
Method: ADPKD subjects were prospectively studied between January 1996 and December 2010. Their demographics, clinical 
and investigation parameters were documented. Dependency on dialysis, renal transplant and death were the final outcomes. 
Results: Forty one patients (M:F=1.3:1) with mean age of  48.6±4.6 years were studied. ADPKD was diagnosed at 2.73 cases 
per annum. Family history of  ADPKD and hypertension were present in 56.1% and 82.9% respectively. Their mean systolic and 
diastolic blood pressures were 166.9 ±23.6 and 104 ±21.2 respectively. 
Nocturia (78.0%) and loin pain (68.3%) were the most common presenting symptoms. Liver cysts (31.7%) and aortic regurgita-
tion (22.0%) were the predominant extra-renal manifestations. 
Twenty three (56.1%) received haemodialysis; no renal transplantation. Death rate was 51.2%. Presence of  uraemia and intra-ce-
rebral aneurysm contributed significantly to mortality. 
Conclusion: ADPKD may not be so rare in Nigeria. Awareness campaign to change attitude of  family members to screening 
and further studies using newer criteria for diagnosis of  ADPKD should be conducted. 
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Introduction 
Autosomal Dominant Polycystic Kidney Disease (ADP-
KD) is the commonest form of  genetically inherited kid-
ney diseases with a prevalence rate of  1:400 to 1:1,000.1 It 
is generally assumed to be rare among Blacks in Africa.2,3 
It ranks as the third leading cause of  End Stage Renal 
Disease (ESRD) and accounts for 5-13.4% of  patients 
undergoing haemodialysis in the United States and Eu-
rope.4-6
In most developed economies, the diagnosis of  ADPKD 
is now made as early as in the first decade of  life due to ad-
vancement in gene technology contrary to resource-poor 
settings such as sub-Saharan Africa where the diagnosis 
of  ADPKD is still restricted to clinical judgement and re-
nal ultrasound. This has hampered knowledge about the 
disease in our setting as demonstrated by the few studies 
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We therefore set out to determine the pattern of  clinical 
presentation and outcome of  ADPKD among patients 
who presented to our renal unit.
Method
Consecutive patients that satisfied the inclusion criteria 
for ADPKD were prospectively followed up over a pe-
riod of  15 years (January 1996 - December 2010) at the 
renal unit, Obafemi Awolowo University Teaching Hos-
pital, Ile-Ife after due approval from the Research and 
Ethics Committee.
Clinical and laboratory evaluations (including medical 
history, physical examination and cardiac examination 
using echocardiogram (Vivid 7, General Electronics, 
USA) were conducted. The diagnosis of  ADPKD was 
established using the Ravine criteria10, presence of  hyper-
tension, multiple liver cysts and family history of  cystic 
kidney disease. Patients with renal cysts who did not ful-
fill the Ravine criteria,patients aged <18 years, those with 
renal malignancy, exophytic cysts, calcifications, tuberous 
sclerosis, or acquired simple cysts were excluded.
Pre-dialysis blood samples were obtained and assessed 
for full blood count and serum chemistry. Urinalysis and 
urine culture were carried out on samples collected un-
der standard techniques. The glomerular filtration rate 
(eGFR) was estimated using the Cockroft and Gault for-
mula.11
Ultrasound scan of  the abdomen was conducted to search 
for presence of  solid organ cysts. Cranial Computerised 
Tomography Scan (CAT scan) or Magnetic Resonance 
Imaging (MRI) were employed where necessary to rule 
out presence of  intra-cranial aneurysm (ICA). Autopsy 
was carried out on all subjects who died during the study 
after due consent from family members. Dependency 
on dialysis, renal transplant and death were the final out-
comes in this study.
Data was analysed using SPSS statistical software version 
17. Continuous variables were expressed as mean±SD, 
median and range. Chi square testing was carried out to 
determine significance (p value < 0.05 at 95% Confidence 
Interval).
Results
A total of  41 patients fulfilled the diagnostic criteria. 
They included 23 (56.1%) males and 18 (43.9%) females 
(M:F=1.3:1). Their age range at the time of  diagnosis was 
18-80 years with mean age of  48.6±4.6 years. The median 
(range) follow up period for all patients was 24 (0.25-84) 
months. The peak age at presentation of  ADPKD was 
between 31-40 years (table 1).
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Table 1: Parameters of ADPKD subjects in OAUTH Ile-Ife (1996-2010) 
 
PARAMETERS MALE FEMALE ALL SUBJECTS 
Baseline parameters  mean ±SD  mean ±SD mean ±SD 
Age at presentation (years) 43.4 (±15.7) 46.3 (±14.3) 48.6±4.6years 
SBP (mmHg) 162.8 (±26.7) 172.2 (±18.3) 166.9 ±23.6 
DBP (mmHg) 104.7 (±23.6) 104.4 (±18.5) 104 ±21.2 
Sodium (mmol/L) 133.2 (±5.9) 135.5 (±3.8) 134.2±5.1 
Potassium (mmol/L) 4.8 (±1.1) 4.4 (±0.9) 4.5±1.0 
Bicarbonate (mmol/L) 20.5 (±2.3) 20.9 (±2.5) 20.6±2.3 
Urea (mmol/L) 18.8 (±9.9) 20.5 (±14.0) 19.5±11.7 
Creatinine (umol/L) 707 (118-2413) 484 (76-3722) 614 (76-3722) 
eGFR (ml/min) 33.2 (±22.2) 35.5 (±25.8) 34.2±23.6 
Haematocrit (%) 27.0 (±4.8) 25.9 (±6.1) 26.5±5.4 
TWCC 5,472.6 (±2344.9) 5,789.3 (±2412.5) 5,611.6±2,350 
 Platelet 180,671.7 (±30,233) 214,777.8 (±139,605.9) 195,645.1±95286.6 
No of HD sessions 5.4 (±5.0) 6.0 (±5.2) 5.6±5.0 
Duration of survival (mo) 24.0 (±24.0) 23.2 (±20.9) 23.6±22.4 
Age at death (years) 46.6±15.8 45.9±14.1 46.3±14.7 
Age of survivors (years) 
  
44.4±16.7 50.3±14.8 47.1±15.8 
Age range, years (N=41) N (%) N (%) N (%) 
            15-20 3 (100%) 0 3 (7.3%) 
            21-30 1 (25%) 3 (75%) 4 (9.8%) 
            31-40 7 (63.6%) 4 (39.4%) 11 (26.9%) 
            41-50 4 (44.5%) 5 (55.5%) 9 (21.9%) 
            51-60 6 (66.7%) 3 (33.3%) 9 (21.9%) 
            61-70 1 (33.3%) 2 (66.7%) 3 (7.3%) 
            >70 1 (50%) 1 (50%) 2 (4.9%) 
JNC hypertension stage 
(N=41) 
      
             pre-hypertension 3 (7.3%) 0 3 (7.3%) 
             stage 1 4 (9.8%) 3 (7.3%) 7 (17.1%) 
             stage 2 16 (39.0%) 15 (36.6%) 31 (75.6%) 
Hypertension by age (N=38)       
            15-20 3 (7.9%) 0 3 (7.9%) 
            21-30 1(2.6%) 3 (7.9%) 4 (10.5%) 
            31-40 6 (14.8%) 4 (10.5%) 10 (26.3%) 
            41-50 3 (7.9%) 5 (13.2%) 8 (21.1%) 
            51-60 5 (13.2%) 3 (7.9%) 8 (21.1%) 
            61-70 1 (2.6%) 2 (5.3%) 3 (7.9%) 
            >71 1 (2.6%) 1 (2.6%) 2 (5.3%) 
Haematocrit % (N=41)       frequency 
            <20 2 (4.9%) 5 (12.2%) 7 (17.1%) 
            20-29 14 (34.2%) 9 (22.0%) 23 (56.1%) 
            30-39 7 (17.1%) 4 (9.8%) 11 (26.8%) 
            ≥40 0 0 0   
SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; N, frequency; 
PCV, packed cell volume; TWCC, total white cell count; HD, haemodialysis; #median/range 
Their baseline parameters are presented in table 1. Their 
mean systolic and diastolic blood pressures were 166.9 
±23.6 and 104 ±21.2 respectively with a median serum 
creatinine of  844µmol/L (range 76-3,722 µmol/L). 
Their mean estimated glomerular filtration rate was 
34.2±23.6ml/min/1.73m2.
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Nocturia (78.0%), loin pain (68.3%) and facial swelling 
(61.0%) were the most common presenting symptoms 
(table 2). Liver cysts (31.7%), aortic regurgitation (22.0%) 
and cerebral aneurysms (14.6%) were the most common 
extra-renal manifestations (table 2). 





   
Frequency by gender 
 
Complaints Frequency (%) Male Female   
Nocturia 32 (78%) 19 13   
Frothy urine 2 (4.9%) 1 1   
Facial swelling 25 (61%) 12 13   
Body swelling 10 (24.4%) 4 6   
Loin pain 28 (68.3%) 16 12   
haematuria 15 (36.6%) 7 8   
LOC 4 (9.8%) 1 3   
Oliguria 24 (58.5%) 14 10   
Stroke 4 (9.8%) 2 2   
Renal findings         
Pallor 35 (85.4%) 18 17   
Hypertension 36 (87.8%) 19 17   
Hepatomegaly 4 (9.8%) 1 3   
Nephromegaly 34 (82.9%) 18 7   
LVH 35 (85.4%) 18 17   
Uraemia 24 (58.5%) 14 10   
Splenomegaly 1 (2.4%) 0 1   
UTI 13 (31.7%) 6 7   
Cystic  haemorrhage 14 (34.2%) 8 6   
Extrarenal findings         
Liver  cysts 13 (31.7%) 6 7   
Splenic cyst 1 (2.4%) 0 1   
Pancreatic cyst 2 (4.9%) 1 1   
Aortic regurgitation 9 (22%) 4 5   
MVP 0 0 0   
Cerebral 
Aneurysm 
6 (14.6%) 3 3   
Ovarian cyst 0 0 0   
LOC, loss of consciousness; LVH, left ventricular hypertrophy; UTI, urinary tract infection; MVP, mitral valve prolapsed 
Fourteen (34.1%) experienced cystic haemorrhage. recur-
rent urinary tract infection was found in 13 (31.7%). End 
Stage Renal Disease was present in 19.5% of  the subjects 
(figure 1).
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Figure 1: KDOQI staging of ADPKD patients in OAUTH Ile-Ife (1996-2010) 
HD, haemodialysis; PD, peritoneal dialysis; RRT, renal replacement therapy 
A range of  1 to 7 cases were diagnosed at an average of  
2.73 cases per annum (table 3). The progression of  ADP-
KD peaked in 2006-2007 and then dropped momentarily 
(table 3). 










1996   0 1 1 (2.4%) 
1997   1 1 2 (4.8%) 
1998   1 1 2 (4.8%) 
1999   0 2 2 (4.8%) 
2000   0 1 1 (2.4%) 
2001   3 0 3 (7.5%) 
2002   3 0 3 (7.5%) 
2003   1 0 1 (2.4%) 
2004   0 2 2 (4.8%) 
2005   2 1 3 (7.8%) 
2006   3 4 7 (17.1%) 
2007   4 3 7 (17.1%) 
2008   3 1 4 (9.8%) 
2009   1 1 2 (4.8%) 
2010   1 0 1 (2.4%) 
Total   23 18 41 (100%) 
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Twenty four (58.5%) subjects presented with renal failure. 
Twenty three (56.1%) of  them volunteered family history 
of  chronic kidney disease. Thirty four (82.9%) had family 
history of  hypertension. However, we could only con-
firm family history of  kidney disease in 3 of  the subjects 
because of  reluctance of  first degree relatives to partici-
pate in screening for ADPKD.
Twenty three (56.1%) received haemodialysis while none 
received renal transplant within the study period (figure 
2). Among the 21 subjects who died during the study 
period, 6 (28.6%) had autopsy-confirmed complications 
arising from ruptured intra-cerebral aneurysm.
 
Figure 2: Utilization of renal replacement therapy by ADPKD patients. 
The average age at death and survival with respect to gen-
der are as shown in table 1. The mean survival was higher 
among women. The presence of  uraemia and intra-cere-
bral aneurysm contributed significantly to mortality (table 
4).








p value (CI, 95%) 
Uraemia  6 18 <0.01 
Ruptured cerebral aneurysm  0  6 0.01 
Female gender  9  9 0.89 
Male gender  11  12 0.89 
Left ventricular hypertrophy  15  20 0.067 
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Discussion
General and renal manifestations
Demography: The male predominance and mean age of  
48.6±4.6 years compares with findings by Chijioke et al 
and other authors.7,12  The peak age of  incidence of  AD-
PKD in our study (3rd and 4th) decade of  life was a bit ear-
lier than 4th to 5th decade found by Chijioke et al.7 Howev-
er, since the advent of  genetic mapping, the diagnosis of  
ADPKD may be made as early as infancy and in-utero.13
A family history of  cystic kidney disease was found in 
56.1% which is comparable to about 60% earlier report-
ed.14-15 However, first degree relatives of  only seven of  
the subjects consented to screening for ADPKD. Three 
of  such family groups were found to have members with 
history of  cystic kidneys verified by history, physical ex-
amination and ultrasonographic criteria for diagnosis of  
ADPKD.
Renal symptoms: Nocturia and loin pain were the most 
common symptoms in our study. Nocturia results from 
inability of  renal tubular cells to re-absorb salt and wa-
ter and may present with normal or increased urine vol-
ume.11 It is often obtained after a careful history taking 
by the physician. Loin pain, on the other hand, was the 
main presenting complaint at presentation (68.3%) and 
is slightly higher than about 60% quoted by Bajwa et al.16 
Acute loin pain (uni- or bilateral) may arise from cystic 
haemorrhage, urolithiasis, mass pressure effect and uri-
nary tract infections.
In our study, 31.7% had urinary tract infection which is 
similar to 35.8% reported by Romao et al.17 It was more 
prevalent among females in conformity with findings by 
previous authors.7,17-19
Majority of  the subjects (73.2%) had haematocrit below 
30%. This is lower than 88.2% reported among an elder-
ly group with ADPKD.21 The high prevalence of  anae-
mia in our study may be linked to late presentation to the 
hospital as shown by 85.4% presenting between KDOQI 
stages 3-5 CKD. Helal et al reported uraemia among their 
subjects at presentation.20 This may also account for the 
absence of  polycythaemia (commonly associated with 
cystic production of  erythropoietin) in our subjects.
Hypertension was highly prevalent in this study. It was 
higher than 73% found byAlves et al. and can reach up 
to nearly 100% of  ADPKD patients with ESRD.18,21 Ma-
jority of  our patients presented with severe hypertension. 
It was more common among men (56.1%) in our study. 
In Dakar, hypertension was found in 61.1% of  their male 
subjects who had ADPKD even though some other stud-
ies reported higher prevalence of  hypertension among 
women.7,17-18,22
Hypertension is known to occur at an earlier age in pa-
tients with ADPKD compared to the general popula-
tion.21 The peak incidence of  hypertension was 31-40 
years in our study which coincides with the peak age at 
presentation of  ADPKD. This is similar to diagnosis of  
hypertension among male and female ADPKD subjects 
aged 32 and 34 years respectively by Schrier et al.23
Left ventricular hypertrophy (LVH) was found in 85.4% 
of  all subjects, higher than 73% reported by Chapman et 
al.24  The occurrence rate of  LVH was higher among our 
normotensive (40% vs 23%) and hypertensive (91.7% vs 
48%) subjects when compared to findings by Chapman 
et al.24
Four (9.8%) of  our subjects presented with loss of  con-
sciousness with radiological imaging revealing a diagnosis 
of  haemorrhagic stroke in three of  them.  Stroke was 
found to occur in 7.6% of  subjects in Brazil17 and has 
been associated with severe hypertension and anuerysmal 
sub-arachnoid haemorrhage in ADPKD patients.
Extra-renal presentations
Solid organ cysts: Polycystic liver disease ranks as the com-
monest extra-renal affectation by ADPKD and can occur 
in more than 80% of  adults with the disease.25  We found 
that 31.7% of  our subjects had polycystic liver which is 
similar to 31.9% and 32.4% reported previously.17,20 A 
lower incidence of  10.4% was reported by Alves et al in 
Brazil among elderly subjects.18 The occurrence of  liver 
cysts (attributed to oestrogen-induced cystic expansion 
and multiplication) was higher among females in this 
study as previously reported by other authors.17,20,26
Cardiac valve anomalies: In our study, aortic regurgitation 
(AR) was the only cardiac anomaly detected by echocar-
diogram. The prevalence was higher than 8% and 19% 
reported earlier.27-28 AR can co-exist with other cardi-
ac-specific anomalies such as mitral valve prolapse, mi-
tral incompetence, tricuspid incompetence and tricuspid 
valve prolapse.27-28
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Intra-cerbral aneurysms (ICA): Dunger was the first to re-
port the association between ADPKD and ICA in 1904.29 
Intra-cerebral aneurysms generally occur in 9–12% of  
ADPKD patients compared to 2–3% in the general pop-
ulation.30 Here, we report an occurrence rate of  autop-
sy-confirmed ICA of  14.6%.  Previous autopsy series re-
ported prevalence ranging between 2.3% and 19.7%.31-32 
Other authors who used Computer Tomographic scan 
and magnetic resonance imaging reported occurrence 
rates of  between 4.5% and 10.8%.33-35
ICA ruptures: Rupture of  aneurysms is the most serious 
complication in ADPKD and may account for 7% to 
13% of  deaths in ADPKD.36 The average age of  ICA 
rupture was 49.2 years in our study, higher than 41 years 
reported by Rivera et al.37 Only two of  the subjects with 
ruptured ICA were diagnosed clinically. This might have 
been due to the sparing use of  angiographic technology 
in our study owing to technicalities and costs.
Other extra-renal manifestations: We were able to demonstrate 
splenic and pancreatic cysts in our subjects but there was 
no evidence of  abdominal hernia or diverticular disease. 
One author reported cysts in seminal vesicle, pancreas 
and arachnoid membrane as well as spinal meningeal and 
connective tissue abnormalities such as abdominal hernia 
and diverticular disease.38
Renal replacement therapy: More than half  of  our subjects 
entered into dialysis with haemodialysis as the predom-
inant modality. Peritoneal dialysis (PD) is considered to 
be more frequently used and to be associated with bet-
ter survival in ADPKD patients.39 In resource-poor set-
tings however, haemodialysis is the preferred option due 
to scarcity of  PD fluids, and associated high costs and 
complications. None of  the subjects received kidney 
transplant due to costs and non-availability of  volunteer 
donors.
Outcome: Mortality was 51.2% in our study. This is over 
two times the figure reported by Chijioke et al.7  Mortal-
ity was higher among males, similar to other findings.40-41 
Specific causes of  death could not be determined as we 
did not conduct autopsy for all subjects. The presence of  
uraemia and intra-cerebral aneurysm was associated with 
mortality. Dalgaard identified uraemia and cerebral haem-
orrhage as the commoner causes of  death in a cohort of  
ADPKD subjects.42 Other factors that have been associ-
ated with mortality in ADPKD patients include cardiac 
disease and infections.40,43-44
Conclusion
The clinical presentation and outcome of  ADPKD are 
comparable to patients from other parts of  the world. 
There is a need for (i) public enlightenment in order to 
encourage relatives of  ADPKD patients to comply with 
screening for ADPKD and, (ii) high-powered, multi-cen-
tred studies that should include use of  gene technology 
for pre-natal and early childhood diagnosis.
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